Terray Therapeutics Achieves Drug Discovery Milestone with Bristol Myers Squibb Using AI-Native EMMI Platform

Terray Therapeutics (搜索)搜索该词条 has achieved a significant discovery milestone in its multi-target collaboration with Bristol Myers Squibb (搜索)搜索该公司, demonstrating the capabilities of its proprietary AI-native drug discovery platform EMMI (搜索)搜索该药品 (Experimentation Meets Machine Intelligence). The milestone represents a breakthrough in applying artificial intelligence to accelerate small molecule drug discovery for challenging therapeutic targets.

EMMI Platform Delivers 3x Efficiency Gains

EMMI (搜索)搜索该药品 combines Terray's proprietary ultra-miniaturized hardware for molecule testing with a highly-automated laboratory and full-stack AI platform. The system is powered by what the company describes as "the most advanced chemistry foundation model in the world," enabling accurate Generate, Predict, and Select models that evaluate millions of molecules to identify optimal candidates for experimental testing.

"EMMI (搜索)搜索该药品 is a platform we have purpose built to solve some of the hardest challenges in drug discovery," said Jacob Berlin, CEO of Terray Therapeutics (搜索)搜索该词条. "Across our internal programs and for our partnership work, EMMI has allowed us to explore the dark matter of chemical space to both find and optimize novel molecules – often for targets with no known starting point."

In benchmarking studies, EMMI (搜索)搜索该药品 demonstrated the ability to reduce both cost and time for iterative molecule optimization by 3x compared to traditional approaches. This efficiency gain stems from the platform's integrated approach that combines generative AI for molecule design, predictive AI for scoring desired properties, and selection AI for guiding which molecules to synthesize and test.

Unprecedented Data Advantage Drives Discovery

Terray has assembled what it claims is the world's largest precise chemistry dataset, powered by the company's proprietary ultra-dense microarray technology. The system generates more than 1 billion new measurements quarterly and has accumulated over 13 billion target-molecule measurements to date. This extensive dataset enables EMMI (搜索)搜索该药品 to identify novel chemistry in areas where traditional approaches have failed.

"Our AI-driven platform discovers and optimizes novel molecules for the difficult-to-drug targets—the ones with no chemistry starting point," Berlin explained. "We are excited about our success together and look forward to further progressing our discovery efforts."

The data advantage has proven crucial for Terray's ability to find structurally-novel molecules across its entire program portfolio, enabling the company to deploy AI models efficiently in newly-identified areas of chemical space.

Multi-Target Collaboration Advances Drug Development

The collaboration with Bristol Myers Squibb (搜索)搜索该公司 leverages EMMI (搜索)搜索该药品's integrated experimental and AI platform to accelerate small molecule drug discovery through rapid, iterative experimentation. The approach combines advanced hardware, AI models, and scientific expertise to streamline identification and development of new therapies for areas with significant unmet medical need.

Terray is advancing both its internal immunology-focused therapeutic portfolio and partnership programs across multiple therapeutic areas, targeting both known and entirely novel drug targets. The company's iterative approach integrates AI with extensive quantitative, structure-activity data to identify optimal molecules for complex drug discovery challenges.

The EMMI (搜索)搜索该药品 platform represents a convergence of machine intelligence, human expertise, and medicine, with Terray continuing to expand its proprietary dataset, refine hardware systems, and train AI models to transform challenging drug discovery problems into viable small-molecule solutions.